TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Extending the Time for Thrombolysis in Emergency Neurological Deficits
Brief Summary: The primary hypothesis being tested in this trial is that ischaemic stroke patients selected with significant penumbral mismatch (measured by MRI criteria) at 3 - 9 hours post onset of stroke will have improved clinical outcomes when given intravenous tissue plasminogen activator (tPA) compared to placebo.


Options:
A: Arm Label: Best medical management.; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Additional intra-arterial treatment.; Type: EXPERIMENTAL; Interventions: Other: Intra-arterial treatment | Intervention Type: OTHER; Name: Intra-arterial treatment; Assigned to Arm(s): Additional intra-arterial treatment.
B: Arm Label: IV tPA; Type: EXPERIMENTAL; Interventions: Drug: Tissue Plasminogen Activator (Alteplase) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tissue Plasminogen Activator (Alteplase); Assigned to Arm(s): IV tPA | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: intravenous tissue plasminogen activator; Type: EXPERIMENTAL; Interventions: Drug: Tissue Plasminogen Activator (Alteplase) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tissue Plasminogen Activator (Alteplase); Assigned to Arm(s): intravenous tissue plasminogen activator | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: intravenous tissue plasminogen activator; Type: EXPERIMENTAL; Interventions: Drug: Alteplase | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Alteplase; Assigned to Arm(s): intravenous tissue plasminogen activator | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Alternative Treatment of Deep Caries Lesions Based on Biological Evidences
Brief Summary: The aim of this multicenter randomized controlled clinical trial is to evaluate the effectiveness of an alternative treatment for deep caries lesions in Public Health Services. The alternative treatment consists of partial removal of carious dentine followed by restoration. The subjects were assigned to test or control groups: test - carious dentine partial removal and restoration in one session, and control - stepwise excavation. The stepwise excavation consists of partial removal of carious tissue from the cavity floor, indirect pulp capping with calcium hydroxide cement; temporary filling; cavity re-opening after 60 days, removal of the remaining soft carious tissue and filling. Each group was divided according to the filling material: amalgam or resin. The radiological exams are being performed before and after the treatment and then annually. Clinical evaluation of the restorations is performed right after the treatment and then annually (modified USPHS System). All evaluations are performed by calibrated and trained dentists.


Options:
A: Arm Label: intervention; Type: EXPERIMENTAL; Interventions: Device: self assembling peptide P11-4 (Curodont™ Repair), Device: fluoride varnish (Duraphat®) | Arm Label: control; Type: ACTIVE_COMPARATOR; Interventions: Device: fluoride varnish (Duraphat®) | Intervention Type: DEVICE; Name: self assembling peptide P11-4 (Curodont™ Repair); Assigned to Arm(s): intervention | Intervention Type: DEVICE; Name: fluoride varnish (Duraphat®); Assigned to Arm(s): control, intervention
B: Arm Label: SW intervention; Type: EXPERIMENTAL; Interventions: Procedure: SW | Arm Label: DCE intervention; Type: OTHER; Interventions: Procedure: DCE | Intervention Type: PROCEDURE; Name: SW; Assigned to Arm(s): SW intervention | Intervention Type: PROCEDURE; Name: DCE; Assigned to Arm(s): DCE intervention
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Partial removal of carious dentine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Stepwise excavation | Intervention Type: PROCEDURE; Name: Partial removal of carious dentine; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Stepwise excavation; Assigned to Arm(s): 2
D: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Device: Mechanical rotary burs | Arm Label: Conservative; Type: EXPERIMENTAL; Interventions: Device: Carisolv gel | Intervention Type: DEVICE; Name: Mechanical rotary burs; Assigned to Arm(s): Control | Intervention Type: DEVICE; Name: Carisolv gel; Assigned to Arm(s): Conservative

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects With Pulmonary Arterial Hypertension
Brief Summary: This study is an international, multi-center, randomized, double-blind, placebo-controlled study in subjects with PAH who are currently receiving approved therapy for their PAH (i.e., endothelin receptor antagonist and/or phosphodiesterase-5 inhibitor). Study visits will occur at 4 week intervals for 16 weeks with the key measure of efficacy being the 6-minute walk test. Study procedures include routine blood tests, medical history, physical exams, disease evaluation, and exercise tests.

Patients who complete all assessments for 16-weeks will also be eligible to enter an open-label, extension phase study (FREEDOM - EXT).


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Ventavis (Iloprost, BAYQ6256) | Intervention Type: DRUG; Name: Ventavis (Iloprost, BAYQ6256); Assigned to Arm(s): Arm 1
B: Arm Label: UT-15C (oral treprositnil); Type: ACTIVE_COMPARATOR; Interventions: Drug: Oral treprostinil (UT-15C) Sustained Release Tablets | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Oral treprostinil (UT-15C) Sustained Release Tablets; Assigned to Arm(s): UT-15C (oral treprositnil) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: UT-15C SR; Type: EXPERIMENTAL; Interventions: Drug: UT-15C SR | Intervention Type: DRUG; Name: UT-15C SR; Assigned to Arm(s): UT-15C SR | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: ACT-293987 (NS-304) and matching placebo; Type: EXPERIMENTAL; Interventions: Device: ACT-293987 (NS-304) | Intervention Type: DEVICE; Name: ACT-293987 (NS-304); Assigned to Arm(s): ACT-293987 (NS-304) and matching placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Renal Denervation in Patients With Uncontrolled Hypertension (Symplicity HTN-2)
Brief Summary: An international, multi-center, prospective, randomized, controlled study of the safety and effectiveness of renal denervation in patients with uncontrolled hypertension.


Options:
A: Arm Label: Renal Denervation; Type: EXPERIMENTAL; Interventions: Device: Renal Denervation | Intervention Type: DEVICE; Name: Renal Denervation; Assigned to Arm(s): Renal Denervation
B: Arm Label: PV isolation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Circumferential PV isolation | Arm Label: PV isolation+renal denervation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: PV isolation+renal denervation | Intervention Type: PROCEDURE; Name: Circumferential PV isolation; Assigned to Arm(s): PV isolation | Intervention Type: PROCEDURE; Name: PV isolation+renal denervation; Assigned to Arm(s): PV isolation+renal denervation
C: Arm Label: Renal Denervation; Type: EXPERIMENTAL; Interventions: Device: Symplicity Spyral™ multi-electrode renal denervation system | Arm Label: Sham Procedure; Type: SHAM_COMPARATOR; Interventions: Procedure: Sham Procedure | Intervention Type: DEVICE; Name: Symplicity Spyral™ multi-electrode renal denervation system; Assigned to Arm(s): Renal Denervation | Intervention Type: PROCEDURE; Name: Sham Procedure; Assigned to Arm(s): Sham Procedure
D: Arm Label: Renal Denervation; Type: EXPERIMENTAL; Interventions: Device: Renal Denervation (Symplicity® Renal Denervation System) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Renal Denervation (Symplicity® Renal Denervation System); Assigned to Arm(s): Renal Denervation

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Renal Denervation in Patients With Uncontrolled Hypertension (Symplicity HTN-2)
Brief Summary: An international, multi-center, prospective, randomized, controlled study of the safety and effectiveness of renal denervation in patients with uncontrolled hypertension.


Options:
A: Arm Label: Renal Denervation; Type: EXPERIMENTAL; Interventions: Device: Renal Denervation (Symplicity® Renal Denervation System) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Renal Denervation (Symplicity® Renal Denervation System); Assigned to Arm(s): Renal Denervation
B: Arm Label: Renal Denervation Treatment; Type: N/A; Interventions: Device: Medtronic Renal Denervation System | Intervention Type: DEVICE; Name: Medtronic Renal Denervation System; Assigned to Arm(s): Renal Denervation Treatment
C: Arm Label: Renal denervation; Type: EXPERIMENTAL; Interventions: Device: MDT-2211 Renal Denervation System | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: MDT-2211 Renal Denervation System; Assigned to Arm(s): Renal denervation
D: Arm Label: Renal Denervation plus Medications; Type: EXPERIMENTAL; Interventions: Device: Radiofrequency ablation catheter, Drug: Amlodipine, losartan potassium and hydrochlorothiazide | Arm Label: Medications; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amlodipine, losartan potassium and hydrochlorothiazide | Intervention Type: DEVICE; Name: Radiofrequency ablation catheter; Assigned to Arm(s): Renal Denervation plus Medications | Intervention Type: DRUG; Name: Amlodipine, losartan potassium and hydrochlorothiazide; Assigned to Arm(s): Medications, Renal Denervation plus Medications

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Secondary Prevention in Uppsala Primary Health Care After Myocardial Infarction, Coronary Artery CABG and PCI. Secondary Prevention After CHD (SUPRIM).
Brief Summary: The purpose of this study is to determine the possible preventive effect of behavioural modification versus standard treatment after hospital discharge in CHD patients.


Options:
A: Arm Label: Intervention Condition (INT); Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced depression care | Arm Label: Usual Cardiologic Care Condition (UCC); Type: OTHER; Interventions: Behavioral: Referred depression care | Intervention Type: BEHAVIORAL; Name: Enhanced depression care; Assigned to Arm(s): Intervention Condition (INT) | Intervention Type: BEHAVIORAL; Name: Referred depression care; Assigned to Arm(s): Usual Cardiologic Care Condition (UCC)
B: Arm Label: ACT-based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: ACT-based intervention, Behavioral: usual care | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: usual care | Intervention Type: BEHAVIORAL; Name: ACT-based intervention; Assigned to Arm(s): ACT-based intervention | Intervention Type: BEHAVIORAL; Name: usual care; Assigned to Arm(s): ACT-based intervention, Usual care
C: Arm Label: Behavioral intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral interventional program | Arm Label: Standard treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Behavioral interventional program | Intervention Type: BEHAVIORAL; Name: Behavioral interventional program; Assigned to Arm(s): Behavioral intervention, Standard treatment
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Interactive Voice Response System | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse-Led Group Clinic Visits | Intervention Type: BEHAVIORAL; Name: Interactive Voice Response System; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Nurse-Led Group Clinic Visits; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Secondary Prevention in Uppsala Primary Health Care After Myocardial Infarction, Coronary Artery CABG and PCI. Secondary Prevention After CHD (SUPRIM).
Brief Summary: The purpose of this study is to determine the possible preventive effect of behavioural modification versus standard treatment after hospital discharge in CHD patients.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Psychotherapy, Other: Usual cardiological care | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Information session, Other: Usual cardiological care | Intervention Type: BEHAVIORAL; Name: Psychotherapy; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Information session; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Usual cardiological care; Assigned to Arm(s): 1, 2
B: Arm Label: Psychotherapy; Type: EXPERIMENTAL; Interventions: Behavioral: Psychotherapy | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Medical therapy | Intervention Type: BEHAVIORAL; Name: Psychotherapy; Assigned to Arm(s): Psychotherapy | Intervention Type: DRUG; Name: Medical therapy; Assigned to Arm(s): Control
C: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Other: Transtheoretical model-based (TTM - based) intervention and motivational interviewing (MI) | Intervention Type: OTHER; Name: Transtheoretical model-based (TTM - based) intervention and motivational interviewing (MI); Assigned to Arm(s): Intervention group
D: Arm Label: Behavioral intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral interventional program | Arm Label: Standard treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Behavioral interventional program | Intervention Type: BEHAVIORAL; Name: Behavioral interventional program; Assigned to Arm(s): Behavioral intervention, Standard treatment

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Activities and Exercise on Sleep in Dementia
Brief Summary: The purpose of the study is to determine whether individualized social activities, physical resistance training and walking, and a combination of both are effective in improving nighttime sleep in elders with dementia.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control Condition | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Individualized Social Activities (ISA) | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Physical Resistance Training and Walking (PRT/walking) | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Behavioral: Combined ISA/PRT/walking | Intervention Type: BEHAVIORAL; Name: Control Condition; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Individualized Social Activities (ISA); Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Physical Resistance Training and Walking (PRT/walking); Assigned to Arm(s): 3 | Intervention Type: BEHAVIORAL; Name: Combined ISA/PRT/walking; Assigned to Arm(s): 4
B: Intervention Type: DRUG; Name: Melatonin; Assigned to Arm(s): N/A
C: Arm Label: Suvorexant; Type: EXPERIMENTAL; Interventions: Drug: Suvorexant | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Suvorexant; Assigned to Arm(s): Suvorexant | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: AZD5213 doseA; Type: EXPERIMENTAL; Interventions: Drug: AZD5213 | Arm Label: AZD5213 doseB; Type: EXPERIMENTAL; Interventions: Drug: AZD5213 | Arm Label: AZD5213 doseC; Type: EXPERIMENTAL; Interventions: Drug: AZD5213 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: AZD5213; Assigned to Arm(s): AZD5213 doseA | Intervention Type: DRUG; Name: AZD5213; Assigned to Arm(s): AZD5213 doseB | Intervention Type: DRUG; Name: AZD5213; Assigned to Arm(s): AZD5213 doseC | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Estudio de Medida Del Riesgo de Caídas Orientada a la Intervención en Residencias
Brief Summary: The aim of the study is to establish the impact of a falls screening questionnaire in the adoption of preventive interventions and eventually in the reduction of falls and its consequences in elder people living in nursing homes.


Options:
A: Arm Label: Enhanced Physical Activity; Type: EXPERIMENTAL; Interventions: Other: Enhanced Physical Activity, Other: Usual Care | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care, Other: Social Interaction | Intervention Type: OTHER; Name: Enhanced Physical Activity; Assigned to Arm(s): Enhanced Physical Activity | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Enhanced Physical Activity, Usual Care | Intervention Type: OTHER; Name: Social Interaction; Assigned to Arm(s): Usual Care
B: Arm Label: LTC Osteoporosis Toolkit Only; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Educ sessions & LTC Osteoporosis toolkit; Type: ACTIVE_COMPARATOR; Interventions: Other: Educ sessions & LTC Osteoporosis toolkit | Intervention Type: OTHER; Name: Educ sessions & LTC Osteoporosis toolkit; Assigned to Arm(s): Educ sessions & LTC Osteoporosis toolkit
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Fall Prevention Tool Kit prototype using a randomized design | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Fall Prevention Tool Kit prototype using a randomized design; Assigned to Arm(s): 1
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Fall risk assessment, Other: Tailored intervention | Arm Label: Control; Type: OTHER; Interventions: Other: Fall risk assessment | Intervention Type: OTHER; Name: Fall risk assessment; Assigned to Arm(s): Control, Intervention | Intervention Type: OTHER; Name: Tailored intervention; Assigned to Arm(s): Intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Technology-Enhanced Quitline Services to Prevent Smoking Relapse
Brief Summary: The purpose of this study is to see if automated telephone monitoring will enhance existing quitline services, such as Alere Wellbeing's Quit For Life program, and help people quit smoking. If successful, this intervention could be incorporated into existing quitline protocols and delivered to millions of people who are trying to quit smoking.


Options:
A: Arm Label: Assisted Referral & IVR; Type: EXPERIMENTAL; Interventions: Behavioral: Assisted referral & IVR | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Assisted referral & IVR; Assigned to Arm(s): Assisted Referral & IVR
B: Arm Label: Telephone Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Telephone Counseling, Behavioral: Brief Hospital Counseling | Arm Label: Nicotine Patches; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patches, Behavioral: Brief Hospital Counseling | Arm Label: Telephone Counseling + Patches; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patches, Behavioral: Telephone Counseling, Behavioral: Brief Hospital Counseling | Arm Label: Brief hospital counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Brief Hospital Counseling | Intervention Type: DRUG; Name: Nicotine Patches; Assigned to Arm(s): Nicotine Patches, Telephone Counseling + Patches | Intervention Type: BEHAVIORAL; Name: Telephone Counseling; Assigned to Arm(s): Telephone Counseling, Telephone Counseling + Patches | Intervention Type: BEHAVIORAL; Name: Brief Hospital Counseling; Assigned to Arm(s): Brief hospital counseling, Nicotine Patches, Telephone Counseling, Telephone Counseling + Patches
C: Arm Label: 2; Type: NO_INTERVENTION; Interventions: Behavioral: Feeback group | Intervention Type: BEHAVIORAL; Name: Feeback group; Assigned to Arm(s): 2
D: Arm Label: Group A; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Behavioral: Quitline Service + 10 automated monitoring calls | Arm Label: Group C; Type: EXPERIMENTAL; Interventions: Behavioral: Quitline service + 20 automated monitoring calls | Intervention Type: BEHAVIORAL; Name: Quitline Service + 10 automated monitoring calls; Assigned to Arm(s): Group B | Intervention Type: BEHAVIORAL; Name: Quitline service + 20 automated monitoring calls; Assigned to Arm(s): Group C

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Technology-Enhanced Quitline Services to Prevent Smoking Relapse
Brief Summary: The purpose of this study is to see if automated telephone monitoring will enhance existing quitline services, such as Alere Wellbeing's Quit For Life program, and help people quit smoking. If successful, this intervention could be incorporated into existing quitline protocols and delivered to millions of people who are trying to quit smoking.


Options:
A: Arm Label: Group A; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Behavioral: Quitline Service + 10 automated monitoring calls | Arm Label: Group C; Type: EXPERIMENTAL; Interventions: Behavioral: Quitline service + 20 automated monitoring calls | Intervention Type: BEHAVIORAL; Name: Quitline Service + 10 automated monitoring calls; Assigned to Arm(s): Group B | Intervention Type: BEHAVIORAL; Name: Quitline service + 20 automated monitoring calls; Assigned to Arm(s): Group C
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Extended IVR (integrated voice response technology), Drug: Varenicline (Champix), Behavioral: IVR treatment | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline (Champix), Behavioral: IVR treatment | Intervention Type: BEHAVIORAL; Name: Extended IVR (integrated voice response technology); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Varenicline (Champix); Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: IVR treatment; Assigned to Arm(s): 1, 2
C: Arm Label: QUIT4Ever; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Drug: nicotine replacement therapy, Other: Smoking cessation counseling, Behavioral: mobile contingency management, Other: Stay Quit Coach | Arm Label: Control Contact Condition; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion, Drug: nicotine replacement therapy, Other: Smoking cessation counseling, Behavioral: mobile contingency management | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Control Contact Condition, QUIT4Ever | Intervention Type: DRUG; Name: nicotine replacement therapy; Assigned to Arm(s): Control Contact Condition, QUIT4Ever | Intervention Type: OTHER; Name: Smoking cessation counseling; Assigned to Arm(s): Control Contact Condition, QUIT4Ever | Intervention Type: BEHAVIORAL; Name: mobile contingency management; Assigned to Arm(s): Control Contact Condition, QUIT4Ever | Intervention Type: OTHER; Name: Stay Quit Coach; Assigned to Arm(s): QUIT4Ever
D: Arm Label: Randomized Phase: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Randomized Phase: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Randomized Phase: Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Randomized Phase: Placebo

Answer: A